Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user!
SYNNEX Corporation (NYSE:SNX) stock lost more than 18 percent Monday morning and hit a new 52-week low of $98.68 in reaction to the company's first quarter earnings report. The business process services company reported a top-and-bottom-line beat in its first quarter report but guided its second quarter EPS to be $2.25 to $2.35 versus expectations of $2.41 per share. Revenue was guided to a range of $4.58 to $4.78 billion versus expectations of $4.75 billion.
Sorl Auto Parts, Inc. (NASDAQ:SORL) stock lost nearly 20 percent. The China-based automotive parts maker reported mixed fourth quarter results but guided its full fiscal year 2018 sales to be $450 million which came in ahead of the consensus estimate of $394 million.
Myriad Genetics, Inc. (NASDAQ:MYGN) stock was trading higher by nearly 2 percent. The company said its wholly-owned subsidiary called Myriad Genetic Laboratories received a manufacturing and marketing approval from Japan's government for its BRACAnalysis Diagnostic System.
Compugen Ltd. (NASDAQ:CGEN) stock gained around 9 percent after the therapeutic discovery and development company announced a new agreement with MedImmune for the development of bi-specific and multi-specific immuno-oncology antibody products. As part of the agreement, Compugen will receive a $10 million upfront payment with up to $200 million in other payments tied to royalties on future sales.
MediciNova, Inc. (NASDAQ:MNOV) stock gained 20 percent. The biopharmaceutical company that focuses on developing treatments for unmet medical needs said over the weekend it can terminate a Phase 2 clinical trial of MN-001 in NASH and NAFLD based on " significant positive results from an interim analysis."
New Quarter Begins: Here Are A Few Trends For Investors To Monitor
28 Stocks Moving In Monday's Pre-Market Session
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!